Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Jan

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Blood Advances|January 31, 2020
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophiliaMax Jan, Daniel E Grinshpun, Julian A Villalba, et al.
ACS Chemical Biology|January 4, 2022
Repurposing the Damage Repair Protein Methyl Guanine Methyl Transferase as a Ligand Inducible Fusion DegronGosia M Murawska, Caspar Vogel, Max Jan, et al.
Leukemia|December 20, 2023
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7Michael C Kann, Emily M Schneider, Antonio J Almazan, et al.
Cancer Cell|April 22, 2022
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaMark B Leick, Harrison Silva, Irene Scarfò, et al.
Nature Chemistry|December 18, 2023
Proteolysis-targeting chimeras with reduced off-targetsTuan M Nguyen, Vedagopuram Sreekanth, Arghya Deb, et al.
Blood Advances|August 3, 2021
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapyPeter G Miller, Adam S Sperling, Elliott J Brea, et al.
Biorxiv : the Preprint Server for Biology|March 22, 2023
A molecular glue approach to control the half-life of CRISPR-based technologiesVedagopuram Sreekanth, Max Jan, Kevin T Zhao, et al.
Cell Chemical Biology|November 21, 2023
Genetic retargeting of E3 ligases to enhance CAR T cell therapyIsabel C Lane, Gabriele Kembuan, Jeannie Carreiro, et al.
Journal of the American Chemical Society|June 30, 2025
A Molecular Glue Approach to Control the Half-Life of CRISPR-Based TechnologiesVedagopuram Sreekanth, Max Jan, Kevin T Zhao, et al.
Nature|April 14, 2022
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursRebecca C Larson, Michael C Kann, Stefanie R Bailey, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Blood Advances|January 31, 2020
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophiliaMax Jan, Daniel E Grinshpun, Julian A Villalba, et al.
ACS Chemical Biology|January 4, 2022
Repurposing the Damage Repair Protein Methyl Guanine Methyl Transferase as a Ligand Inducible Fusion DegronGosia M Murawska, Caspar Vogel, Max Jan, et al.
Leukemia|December 20, 2023
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7Michael C Kann, Emily M Schneider, Antonio J Almazan, et al.
Cancer Cell|April 22, 2022
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaMark B Leick, Harrison Silva, Irene Scarfò, et al.
Nature Chemistry|December 18, 2023
Proteolysis-targeting chimeras with reduced off-targetsTuan M Nguyen, Vedagopuram Sreekanth, Arghya Deb, et al.
Blood Advances|August 3, 2021
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapyPeter G Miller, Adam S Sperling, Elliott J Brea, et al.
Biorxiv : the Preprint Server for Biology|March 22, 2023
A molecular glue approach to control the half-life of CRISPR-based technologiesVedagopuram Sreekanth, Max Jan, Kevin T Zhao, et al.
Cell Chemical Biology|November 21, 2023
Genetic retargeting of E3 ligases to enhance CAR T cell therapyIsabel C Lane, Gabriele Kembuan, Jeannie Carreiro, et al.
Journal of the American Chemical Society|June 30, 2025
A Molecular Glue Approach to Control the Half-Life of CRISPR-Based TechnologiesVedagopuram Sreekanth, Max Jan, Kevin T Zhao, et al.
Nature|April 14, 2022
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursRebecca C Larson, Michael C Kann, Stefanie R Bailey, et al.
Pageof 4